Literature DB >> 20067797

High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells.

Bin Du1, Li-Ming Ma, Mian-Bo Huang, Hui Zhou, Hui-Lin Huang, Peng Shao, Yue-Qin Chen, Liang-Hu Qu.   

Abstract

Deposition of collagen IV in proximal tubule cells (PTCs) plays an important role during diabetic nephropathy, but the mechanism underlying excessive production of collagen IV remains poorly understood. In this study, we examined the miRNA profile of HK-2 cells and found that high glucose/TGF-beta1 induced significant down-regulation of miR-29a. We then showed that miR-29a negatively regulated collagen IV by directly targeting the 3'UTRs of col4a1 and col4a2. These results suggest that miR-29a acts as a repressor to fine-tune collagen expression and that the reduction of miR-29a caused by high glucose may increase the risk of excess collagen deposition in PTCs. Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067797     DOI: 10.1016/j.febslet.2009.12.053

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  70 in total

1.  Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Jianming Qiu; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

Review 2.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

3.  Thrombin down-regulates the TGF-beta-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1.

Authors:  Jong-Sup Bae; In-San Kim; Alireza R Rezaie
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

Review 4.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 5.  MicroRNAs as mediators and therapeutic targets in chronic kidney disease.

Authors:  Johan M Lorenzen; Hermann Haller; Thomas Thum
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

6.  Differential expression and therapeutic efficacy of microRNA-346 in diabetic nephropathy mice.

Authors:  Yong Zhang; Hou-Qin Xiao; Yang Wang; Zhuo-Shun Yang; Long-Jun Dai; Yan-Cheng Xu
Journal:  Exp Ther Med       Date:  2015-04-30       Impact factor: 2.447

Review 7.  MicroRNAs and the glomerulus.

Authors:  Mitsuo Kato; Jung Tak Park; Rama Natarajan
Journal:  Exp Cell Res       Date:  2012-03-05       Impact factor: 3.905

8.  RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Christopher J Rhodes; Hogune Im; Aiqin Cao; Jan K Hennigs; Lingli Wang; Silin Sa; Pin-I Chen; Nils P Nickel; Kazuya Miyagawa; Rachel K Hopper; Nancy F Tojais; Caiyun G Li; Mingxia Gu; Edda Spiekerkoetter; Zhaoying Xian; Rui Chen; Mingming Zhao; Mark Kaschwich; Patricia A Del Rosario; Daniel Bernstein; Roham T Zamanian; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

9.  microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Amit Bera; Nandini Ghosh-Choudhury; Falguni Das; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Exp Cell Res       Date:  2018-02-01       Impact factor: 3.905

10.  Transforming growth factor β-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium.

Authors:  Jun Wang; Youliang Wang; Yu Wang; Ying Ma; Yu Lan; Xiao Yang
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.